论文部分内容阅读
目的探讨前列地尔联合低分子右旋糖苷治疗糖尿病足的临床效果和安全性。方法将我院2005年9月以来收治的符合入选条件80例患者随机分为治疗组和对照组各40例,在常规治疗基础上治疗组用前列地尔与低分子右旋糖苷,对照组用脉络宁。两组分别治疗20d进行ABI、血流速度、足背动脉内径评价临床疗效。结果治疗组治愈率75%、好转率17.5%、无效7.5%;对照组治愈率45%、好转率32.5%、无效22.5%,治疗组明显优于对照组,差异有统计学意义(P<0.01)。结论前列地尔联合低分子右旋糖苷治疗糖尿病足疗效满意,值得推广。
Objective To investigate the clinical efficacy and safety of alprostadil combined with low molecular weight dextran in the treatment of diabetic foot. Methods Eighty patients eligible for inclusion in our hospital since September 2005 were randomly divided into treatment group (40 cases) and control group (40 cases). On the basis of routine treatment, the treatment group was treated with alprostadil and low molecular weight dextran, while the control group Mailuoning. Two groups were treated 20d ABI, blood flow velocity, dorsalis pedis artery diameter evaluation of clinical efficacy. Results The cure rate of the treatment group was 75%, the improvement rate was 17.5% and the invalid rate was 7.5%. The cure rate of the control group was 45%, the improvement rate was 32.5% and the ineffectiveness was 22.5%. The treatment group was significantly better than the control group (P <0.01) ). Conclusion Alprostadil combined with low molecular weight dextran treatment of diabetic foot satisfaction, worth promoting.